soon
first
describ
aptam
larg
recogn
new
class
biolog
ligand
rival
antibodi
variou
analyt
diagnost
therapeut
applic
aptam
short
singlestrand
rna
dna
oligonucleotid
capabl
fold
complex
structur
enabl
bind
larg
varieti
target
rang
small
ion
entir
organ
high
bind
specif
affin
make
compar
antibodi
superior
regard
longer
shelf
life
simpl
product
chemic
modif
addit
low
toxic
immunogen
past
three
decad
aptam
use
plethora
therapeut
drug
deliveri
system
involv
innov
deliveri
mechan
carri
variou
type
drug
cargo
howev
success
translat
aptam
research
bench
bedsid
challeng
sever
limit
slow
realiz
promis
aptam
applic
therapeut
clinic
level
main
limit
includ
suscept
degrad
nucleas
fast
renal
clearanc
low
thermal
stabil
limit
function
group
divers
solut
overcom
limit
lie
chemistri
aptam
current
review
focu
recent
art
aptam
chemistri
evolv
refin
pharmacolog
properti
aptam
moreov
review
analyz
advantag
disadvantag
chemic
modif
impact
pharmacolog
properti
aptam
final
review
summar
conjug
strategi
aptam
nanocarri
develop
target
drug
deliveri
system
molecul
molecul
nowaday
aptam
field
cover
variou
biomed
applic
includ
therapeut
aptasensor
biosensor
diagnost
imag
system
aptam
need
stabil
vivo
use
nucleas
degrad
small
size
make
suscept
renal
filtrat
aptam
stabil
attain
chemic
modifi
use
differ
approach
moreov
introduc
chemic
modif
nucleic
acid
librari
increas
interact
capabl
aptam
therebi
target
spectrum
modifi
aptam
may
show
improv
chemic
divers
rel
aptam
compos
entir
natur
dna
rna
nucleotid
expand
applic
diagnost
therapeut
nanotechnolog
chemic
modif
aptam
oligonucleotid
need
mainli
enhanc
resist
nucleas
degrad
lower
renal
filtrat
addit
chemic
modif
case
may
increas
aptamerbind
affin
mani
approach
introduc
promot
stabil
aptam
without
alter
bind
affin
specif
target
approach
includ
chemic
modif
phosphat
backbon
oxygen
replac
sulfur
ribos
unit
phosphodiest
linkag
end
cap
andor
termin
lock
nucleic
acid
circular
multival
dimer
aptam
modif
posit
ribos
sugar
common
aptam
chemic
modif
strategi
also
requir
conjug
aptam
differ
drug
molecul
activ
target
nanoparticl
strategi
usual
introduc
activ
function
either
termin
oligonucleotid
interact
coupl
partner
surfac
nanoparticl
sever
coupl
chemistri
method
appli
aptam
conjug
includ
thiolmaleimid
carbodiimid
oxid
coupl
thiolgold
coordin
avidinbiotin
coupl
click
chemistri
aptam
singlestrand
rna
dna
oligonucleotid
fold
distinct
structur
capabl
bind
high
affin
specif
small
molecul
entir
organ
nanomolar
rang
dissoci
constant
nucleic
acidbas
aptam
first
describ
first
aptam
vitro
select
use
random
librari
singlestrand
oligonucleotid
sequenc
select
procedur
known
systemat
evolut
ligand
exponenti
enrich
selex
first
oligonucleotid
aptam
isol
bind
small
enrich
oligonucleotid
librari
without
ion
salt
gener
aptam
function
presenc
metal
ion
salt
crossoverselex
first
oligonucleotid
enrich
use
cellselex
product
cellselex
enrich
purifi
protein
yield
higher
bind
affin
crossoverselex
use
target
rare
origin
environ
subtract
selex
select
aptam
abil
differenti
two
close
relat
target
eg
distinguish
normal
cell
structur
anoth
diseaserel
one
obtain
ad
round
neg
select
normal
cell
condit
selex
select
aptam
affect
presenc
regulatori
molecul
aptam
select
perform
two
stage
first
stage
presenc
regulatori
molecul
second
absenc
regulatori
molecul
sequenc
success
bind
target
either
one
stage
select
depend
whether
aptam
use
presenc
absenc
regulatori
molecul
onchip
select
similar
microarray
method
singl
doubl
base
variat
introduc
use
silico
method
preselect
sequenc
highest
affin
target
embed
surfac
plasmon
reson
spr
chip
onchip
select
use
aptam
select
larg
number
target
immobilizationfre
selex
goselex
first
librari
incub
target
graphen
oxid
go
ad
mix
order
bind
unbound
sequenc
via
pp
stack
tissu
slidebas
selex
select
aptam
clinic
sampl
cancer
tissu
use
first
stage
target
tissu
scrape
slide
bound
sequenc
sequenc
elut
counter
select
normal
tissu
perform
elimin
share
aptam
capillari
electrophoresi
selex
ceselex
ceselex
separ
target
bound
unbound
sequenc
differ
electrophoret
mobil
highli
effici
separ
method
method
enabl
select
aptam
candid
high
affin
reduc
select
round
nearli
convent
selex
microfluid
selex
mselex
combin
tradit
selex
microfluid
system
system
contain
reagentload
microlin
pressur
reagent
reservoir
manifold
pcr
thermocycl
actuat
valv
select
sampl
rout
highthroughput
sequenc
selex
htsselex
aptam
identifi
iter
process
evolutionari
select
start
random
pool
contain
billion
sequenc
predomin
characterist
htsselex
firstli
allow
sequenc
librari
across
select
round
thu
enrich
sequenc
visibl
much
earlier
round
time
effici
fewer
select
round
also
avoid
potenti
pcr
bia
caus
select
anoth
selex
variant
vivo
selex
method
gener
aptam
target
live
organ
instead
use
isol
pure
target
individu
cell
method
use
overcom
challeng
face
aptam
select
vitro
selex
method
principl
similar
convent
selex
cell
selex
howev
librari
aptam
inject
peripher
vasculatur
live
organ
follow
track
isol
specif
aptam
home
target
tissu
vivo
selex
success
appli
differ
aptam
modif
also
report
enhanc
stabil
figur
attach
thrombin
aptam
investig
activ
blood
rodent
result
show
modif
significantli
enhanc
resist
decreas
clearanc
rate
aptam
blood
circul
vivo
modifieddna
aptam
target
sever
acut
respiratori
syndrom
sar
coronaviru
helicas
sustain
fetal
bovin
serum
fb
doubl
time
compar
unmodifi
aptam
moreov
stabil
select
non
gquadruplex
aptam
modifi
thymidin
increas
thymidin
aptam
strongli
moreov
stabil
select
non
gquadruplex
aptam
modifi
biotin
invert
thymidin
increas
biotin
invert
thymidin
aptam
strongli
resist
nucleas
attack
serum
compar
unmodifi
aptam
invert
thymidin
aptam
remain
intact
h
fb
respect
invert
thymidin
modif
show
higher
stabil
biotin
modif
modif
significantli
stabl
unmodifi
aptam
riccardi
et
al
synthes
character
dansylfluoresc
thrombinbind
aptam
tba
analog
name
trismtba
function
biotin
tag
incorpor
onto
streptavidinco
silica
np
result
show
trismtbawa
abl
form
antiparallel
gquadruplex
structur
retain
abil
form
duplex
structur
complementari
strand
ctba
act
antidot
revers
anticoagul
activ
tba
moreov
prove
trismtba
inhibit
human
thrombin
activ
effici
unmodifi
tba
biotintba
revers
manner
addit
tba
analog
show
higher
resist
enzymat
degrad
compar
unmodifi
tba
due
protect
effect
conjug
group
ortigao
et
al
found
minor
structur
chang
oligonucleotid
two
termin
internucleotid
bond
linkag
suffici
stabil
endinvert
inv
oligonucleotid
nucleas
degrad
inv
oligonucleotid
degrad
slowli
biolog
system
human
serum
halflif
h
xenopuslaevi
oocyt
halflif
h
wherea
control
normal
oligonucleotid
complet
degrad
less
min
system
small
aptam
clear
excret
rapidli
renal
glomerular
filtrat
overcom
renal
filtrat
extend
circul
period
aptam
modif
hydrophob
andor
bulki
moieti
requir
cholesterol
conjug
end
oligonucleotid
odn
phosphat
spacer
incub
lowdens
lipoprotein
ldl
lead
format
cholodnldl
plasma
halflif
cholodnldl
aptam
nearli
time
better
plasma
halflif
unmodifi
aptam
furthermor
modifi
cholodnldl
version
show
high
stabil
rat
serum
nucleas
recent
cholesterolconjug
f
pyrimidinemodifi
rna
aptam
target
hepat
c
viru
hcv
protein
modifi
lee
et
al
aptam
modif
extend
aptam
plasma
circul
time
ninefold
compar
unmodifi
version
enhanc
aptam
exposur
target
anoth
case
cholesterolmodifi
oligonucleotid
show
rapid
plasma
clearanc
rel
unconjug
aptam
explain
inabl
fold
structur
bind
plasma
lipoprotein
cholesterolattach
aptam
diacylglycerol
dag
lipid
anchor
conjug
end
vascular
endotheli
growth
factor
vegf
aptam
figur
end
dagmodifi
vegf
aptam
incorpor
bilay
liposom
result
aptam
improv
inhibitori
activ
toward
vegfinduc
endotheli
cell
prolifer
vitro
increas
vascular
permeabl
vivo
moreov
resid
time
plasma
consider
improv
compar
free
aptam
set
lipid
conjug
aptam
stearylor
cholesterylbas
tail
figur
select
investig
conform
behavior
aggreg
tendenc
comparison
unmodifi
deriv
fold
stabl
unimolecular
gquadruplex
structur
form
larg
aggreg
concentr
higher
maintain
similar
biolog
behavior
unmodifi
aptam
less
cytotox
select
three
differ
cancer
cell
line
set
lipid
conjug
aptam
stearylor
cholesterylbas
tail
figur
select
investig
conform
behavior
aggreg
tendenc
comparison
unmodifi
lipid
deriv
fold
stabl
unimolecular
gquadruplex
structur
form
larg
aggreg
concentr
higher
maintain
similar
biolog
behavior
unmodifi
aptam
less
cytotox
select
three
differ
cancer
cell
line
set
lipid
conjug
aptam
stearylor
cholesterylbas
tail
figur
select
investig
conform
behavior
aggreg
tendenc
comparison
unmodifi
deriv
fold
stabl
unimolecular
gquadruplex
structur
form
larg
aggreg
concentr
higher
maintain
similar
biolog
behavior
unmodifi
aptam
less
cytotox
select
three
differ
cancer
cell
line
conjug
polyethylen
glycol
peg
drug
shown
increas
resid
time
drug
bodi
decreas
degrad
metabol
enzym
peg
nontox
nonimmunogen
approv
food
drug
administr
fda
aminomodifi
spiegelm
oligonucleotid
conjug
nh
esteractiv
polyethylen
glycol
via
carbodiimid
coupl
combin
formula
high
molecular
weight
peg
advantag
nucleas
resist
decreas
renal
excret
dna
aptam
bind
murin
extracellular
domain
program
death
protein
conjug
dna
aptam
larg
peg
molecul
termin
via
carbodiimid
chemistri
figur
could
limit
rate
filtrat
extend
halflif
small
molecul
h
molecul
x
peer
review
conjug
polyethylen
glycol
peg
drug
shown
increas
resid
time
drug
bodi
decreas
degrad
metabol
enzym
peg
nontox
nonimmunogen
approv
food
drug
administr
fda
aminomodifi
spiegelm
oligonucleotid
conjug
nh
esteractiv
polyethylen
glycol
via
carbodiimid
coupl
combin
formula
high
molecular
weight
peg
advantag
nucleas
resist
decreas
renal
excret
dna
aptam
bind
murin
extracellular
domain
program
death
protein
conjug
dna
aptam
larg
peg
molecul
termin
via
carbodiimid
chemistri
figur
could
limit
rate
filtrat
extend
halflif
small
molecul
h
interest
new
pegyl
method
sbcpegyl
introduc
recent
rna
aptam
act
mice
monkey
sbcpegyl
aptam
synthes
coupl
symmetr
branch
molecul
ndiisopropyl
phosphoramidit
end
aptam
conjug
two
peg
molecul
aptam
sbcpegyl
aptam
improv
pharmacokinet
properti
show
excel
stabil
blood
circul
moreov
one
sbcpegyl
aptam
inhibit
concentrationdepend
manner
two
time
lower
nonpegyl
bifunction
aptam
nh
aptasr
conjug
differ
peg
type
either
convent
branch
peg
combshap
polypeg
enhanc
biodistribut
properti
cell
line
bodi
clearanc
data
show
unpegyl
aptam
excret
h
compar
case
newli
modifi
aptam
pegyl
doxorubicinattach
aptam
pegaptdox
increas
target
efficaci
aptam
reduc
nonspecif
uptak
doxorubicin
raw
macrophag
pegaptdox
kept
raw
cell
viabl
kill
cell
prove
desir
cytotox
effect
doxorubicin
cell
hinder
modif
interest
new
pegyl
method
sbcpegyl
introduc
recent
rna
aptam
act
mice
monkey
sbcpegyl
aptam
synthes
coupl
symmetr
branch
molecul
ndiisopropyl
phosphoramidit
end
aptam
conjug
two
peg
molecul
aptam
sbcpegyl
aptam
improv
pharmacokinet
properti
show
excel
stabil
blood
circul
moreov
one
sbcpegyl
aptam
inhibit
concentrationdepend
manner
ic
two
time
lower
nonpegyl
bifunction
aptam
nh
aptasr
conjug
differ
peg
type
either
convent
branch
peg
combshap
polypeg
enhanc
biodistribut
properti
cell
line
bodi
clearanc
data
show
unpegyl
aptam
excret
h
compar
case
newli
modifi
aptam
pegyl
doxorubicinattach
aptam
pegaptdox
increas
target
efficaci
aptam
reduc
nonspecif
uptak
doxorubicin
raw
macrophag
pegaptdox
kept
raw
cell
viabl
kill
cell
prove
desir
cytotox
effect
doxorubicin
cell
hinder
modif
modif
posit
sugar
effect
improv
aptam
serum
halflif
fluoro
f
amino
nh
omethyl
ome
common
substitut
modif
ribos
unit
usual
use
increas
nucleas
resist
optim
aptam
affin
figur
molecul
x
peer
review
modif
posit
sugar
effect
improv
aptam
serum
halflif
common
modif
ribos
unit
usual
use
increas
nucleas
resist
optim
aptam
affin
figur
exampl
two
thrombinbind
aptam
show
approxim
fourfold
increas
bind
affin
thrombin
sevenfold
higher
nucleas
resist
gquadruplex
stabil
modifi
aptam
increas
fb
lin
et
al
develop
groupmodifi
rna
aptam
human
neutrophil
elastas
hne
modifi
aptam
show
good
bind
affin
enhanc
stabil
human
serum
urin
compar
unmodifi
aptam
highaffin
rna
ligand
report
potent
inhibitor
basic
fibroblast
growth
factor
bfgf
compar
unmodifi
rna
sequenc
ligand
least
stabl
human
serum
rna
dna
aptam
bind
vascular
permeabl
factorvascular
endotheli
growth
factor
vpfvegf
investig
green
et
al
show
nucleas
resist
properti
high
bind
affin
pagrati
et
al
demonstr
vitro
selectionamplif
random
librari
rna
molecul
contain
rna
ligand
higher
bind
affin
kd
rang
pm
compar
pm
bioactiv
exampl
two
fmodifi
thrombinbind
aptam
show
approxim
fourfold
increas
bind
affin
thrombin
sevenfold
higher
nucleas
resist
gquadruplex
stabil
modifi
aptam
increas
fb
lin
et
al
develop
nh
groupmodifi
rna
aptam
human
neutrophil
elastas
hne
modifi
aptam
show
good
bind
affin
enhanc
stabil
human
serum
urin
compar
unmodifi
aptam
highaffin
deoxypyrimidinemodifi
rna
ligand
report
potent
inhibitor
basic
fibroblast
growth
factor
bfgf
compar
unmodifi
rna
sequenc
aminopyrimidin
ligand
least
stabl
human
serum
aminomodifi
rna
dna
aptam
bind
vascular
permeabl
factorvascular
endotheli
growth
factor
vpfvegf
investig
green
et
al
show
nucleas
resist
properti
high
bind
affin
pagrati
et
al
demonstr
vitro
selectionamplif
random
librari
rna
molecul
contain
nh
deoxypyrimidin
f
rna
ligand
higher
bind
affin
k
rang
pm
f
compar
pm
nh
bioactiv
extrem
thermost
compar
nh
ligand
pegaptanib
multimodifi
rna
aptam
bind
high
affin
human
vascular
endotheli
growth
factor
treatment
neovascular
agerel
macular
degener
amd
exampl
aptamerbas
drug
current
approv
fda
maio
et
al
design
omethyl
rna
analog
dna
aptam
result
increas
aptam
stabil
toward
nucleas
h
without
affect
affin
myeloid
leukemia
addit
antivegf
combin
use
fluoro
methyl
pyrimidin
ntp
wildtyp
purin
ntp
follow
postselect
modif
unmodifi
ribonucleotid
methoxi
modif
aptam
bind
equal
well
murin
bind
smaller
isoform
placenta
growth
factor
show
reduc
signific
affin
heterodim
modif
li
et
al
select
isol
nucleasest
fluoropyrimidinemodifi
antiegfr
aptam
target
four
member
epiderm
growth
factor
receptor
egfr
famili
promis
aptam
strong
bind
affin
k
nm
wildtyp
receptor
lead
cell
prolifer
inhibit
esposito
et
al
isol
fluoropyrimidinemodifi
antiegfr
show
high
bind
affin
lung
cancer
cell
line
fluoromodifi
rna
aptam
gener
prostatespecif
antigen
psa
modifi
aptam
highli
stabl
human
serum
show
modest
affin
k
nm
psa
addit
frna
aptam
isol
test
potenti
treatment
human
prostat
cancer
cell
via
prostatespecif
membran
antigen
k
nm
interest
aptam
aptam
fluoropyrimidin
modifi
rna
aptam
aptam
isol
brain
mice
vivo
selex
mice
tail
inject
fluoromodifi
rna
librari
isol
aptam
modifi
methoxi
residu
increas
nucleas
resist
test
brain
penetr
biodistribut
aptam
verifi
posit
signal
differ
brain
region
recent
thirunavukarasu
et
al
report
select
two
type
f
purin
aptam
bind
human
neutrophil
elastas
hne
bind
hne
reason
affin
f
purin
substitu
enhanc
nucleas
resist
despit
methoxi
modif
one
postselect
procedur
due
bulki
omentp
combin
three
omentp
use
selex
experi
gener
aptam
bind
polypeptid
tissu
factor
pathway
inhibitor
tfpi
modifi
aptam
show
high
select
bind
affin
correct
thrombin
gener
hemophilia
b
modifi
aptam
easili
conjug
unmodifi
aptam
differ
nanocarri
load
certain
chemotherapeut
agent
exampl
omemodifi
aptam
conjug
polymer
nanoparticl
load
docetaxel
anticanc
agent
show
high
specif
well
target
toxic
improv
fluoromodifi
arabinonucleotid
fana
investig
base
thrombinbind
dna
aptam
ggttggtgtggttgg
antihiv
phosphorothio
psd
ttggggtt
dna
telomer
sequenc
ggggttttgggg
uv
thermal
denatur
tm
circular
dichroism
cd
experi
result
show
replac
deoxyguanosin
adopt
anticonform
antiguanin
farabino
guanosin
stabil
gquartet
maintain
quadruplex
conform
replac
synguanin
farabino
guanosin
favor
result
dramat
switch
altern
quadruplex
conform
addit
data
show
appropri
incorpor
fana
residu
gquadruplex
lead
increas
melt
temperatur
complex
form
moreov
nucleas
resist
fanamodifi
thrombinbind
aptam
increas
fb
enhanc
bind
affin
thrombin
similarli
wild
damha
use
uv
thermal
melt
cd
experi
discov
thermodynam
stabil
helic
conform
fanarna
fanadna
hybrid
show
fana
enhanc
rna
affin
rnase
h
enzym
rel
dna
phosphorothio
dna
fana
modif
also
show
favor
pair
singlestrand
dna
stabil
fluoroarabinonucl
acid
fana
hydrolysi
investig
acid
basic
condit
fana
found
increas
stabil
compar
dna
rna
enzymefre
simul
gastric
fluid
basic
condit
fana
also
show
good
stabil
furthermor
fana
linkag
found
much
suscept
enzymat
cleavag
phosphorothioatedna
differenti
stabil
fana
rna
ana
rna
hybrid
duplex
evalu
nmr
theoret
calcul
increas
bind
affin
fana
observ
due
favor
pseudo
hydrogen
bond
fpurin
contrast
unfavor
ohnucleobas
steric
interact
case
ana
fana
strand
structur
compat
alik
structur
hybrid
duplex
suitabl
reorgan
duplex
format
replac
oxygen
atom
sugar
unit
sulfur
atom
rare
util
select
experi
aptam
isol
figur
synthes
thiouridin
thioutp
thiocytidin
thioctp
triphosph
use
vitro
select
antithrombin
thiorna
aptam
thiomodifi
aptam
show
high
affin
k
nm
increas
resist
rnase
minakawa
et
al
isol
fulli
modifi
thiorna
aptam
human
alphathrombin
use
four
type
thioribonucleosid
triphosph
thiontp
modifi
aptam
display
similar
bind
affin
thrombin
partial
modifi
aptam
k
nm
dna
phosphorothio
dna
modif
also
show
favor
pair
singlestrand
dna
stabil
acid
hydrolysi
investig
acid
basic
condit
found
increas
stabil
compar
dna
rna
enzymefre
simul
gastric
fluid
ph
basic
condit
also
show
good
stabil
furthermor
linkag
found
much
suscept
enzymat
cleavag
phosphorothioatedna
differenti
stabil
fana
rna
ana
rna
hybrid
duplex
evalu
nmr
theoret
calcul
increas
bind
affin
fana
observ
due
favor
pseudo
hydrogen
bond
fpurin
contrast
unfavor
steric
interact
case
ana
fana
structur
compat
alik
structur
hybrid
duplex
suitabl
reorgan
duplex
format
replac
atom
sugar
unit
sulfur
atom
rare
util
select
experi
aptam
isol
figur
synthes
triphosph
use
vitro
select
antithrombin
thiorna
aptam
aptam
show
high
affin
kd
nm
increas
resist
rnase
minakawa
et
al
isol
fulli
modifi
aptam
human
alphathrombin
use
four
type
triphosph
modifi
aptam
display
similar
bind
affin
thrombin
partial
modifi
aptam
kd
nm
base
figur
structur
methylen
linkag
sugar
ring
produc
analog
ribonucleotid
call
lock
nucleic
acid
lna
figur
modif
show
better
thermost
vastli
enhanc
nucleas
resist
methylen
linkag
c
sugar
ring
produc
analog
ribonucleotid
call
lock
nucleic
acid
lna
figur
modif
show
better
thermost
vastli
enhanc
nucleas
resist
dna
phosphorothio
dna
modif
also
show
favor
pair
singlestrand
dna
stabil
acid
hydrolysi
investig
acid
basic
condit
found
increas
stabil
compar
dna
rna
enzymefre
simul
gastric
fluid
ph
basic
condit
also
show
good
stabil
furthermor
linkag
found
much
suscept
enzymat
cleavag
phosphorothioatedna
differenti
stabil
fana
rna
ana
rna
hybrid
duplex
evalu
nmr
theoret
calcul
increas
bind
affin
fana
observ
due
favor
pseudo
hydrogen
bond
fpurin
contrast
unfavor
steric
interact
case
ana
fana
structur
compat
alik
structur
hybrid
duplex
suitabl
reorgan
duplex
format
replac
atom
sugar
unit
sulfur
atom
rare
util
select
experi
aptam
isol
figur
synthes
triphosph
use
vitro
select
antithrombin
thiorna
aptam
aptam
show
high
affin
kd
nm
increas
resist
rnase
minakawa
et
al
isol
fulli
modifi
aptam
human
alphathrombin
use
four
type
triphosph
modifi
aptam
display
similar
bind
affin
thrombin
partial
modifi
aptam
kd
nm
base
figur
structur
methylen
linkag
sugar
ring
produc
analog
ribonucleotid
call
lock
nucleic
acid
lna
figur
modif
show
better
thermost
vastli
enhanc
nucleas
resist
lnadna
chimera
form
stabl
complex
transactiv
respons
tar
rna
synthes
shorten
stabl
version
hairpin
rna
aptam
identifi
vitro
select
tar
result
indic
modif
provid
good
protect
toward
nucleas
digest
bovin
serum
keep
bind
affin
unmodifi
rna
aptam
shi
et
al
develop
anoth
lnadna
chimer
aptam
probe
proper
lna
incorpor
thymidin
cap
figur
serum
stabil
modifi
aptam
dna
aptam
lymphoma
ramo
cell
gradual
enhanc
maintain
affin
specif
ramo
cell
vitro
select
tar
result
indic
modif
provid
good
protect
toward
nucleas
digest
bovin
serum
keep
bind
affin
unmodifi
rna
aptam
shi
et
al
develop
anoth
lnadna
chimer
aptam
probe
proper
lna
incorpor
cap
figur
serum
stabil
modifi
aptam
dna
aptam
lymphoma
ramo
cell
gradual
enhanc
maintain
affin
specif
ramo
cell
tenascincbind
aptam
modifi
lna
nucleotid
exhibit
improv
plasma
stabil
maintain
strong
bind
tenascinc
moreov
avidinbind
dna
aptam
modifi
systemat
lna
deriv
demonstr
figur
certain
posit
modifi
aptam
actual
show
improv
bind
affin
kd
valu
nm
tenascincbind
aptam
modifi
lna
nucleotid
exhibit
improv
plasma
stabil
maintain
strong
bind
tenascinc
moreov
avidinbind
dna
aptam
modifi
systemat
lna
amino
deriv
demonstr
figur
certain
posit
modifi
aptam
actual
show
improv
bind
affin
k
valu
nm
rna
synthes
shorten
stabl
version
hairpin
rna
aptam
identifi
vitro
select
tar
result
indic
modif
provid
good
protect
toward
nucleas
digest
bovin
serum
keep
bind
affin
unmodifi
rna
aptam
shi
et
al
develop
anoth
lnadna
chimer
aptam
probe
proper
lna
incorpor
cap
figur
serum
stabil
modifi
aptam
dna
aptam
lymphoma
ramo
cell
gradual
enhanc
maintain
affin
specif
ramo
cell
tenascincbind
aptam
modifi
lna
nucleotid
exhibit
improv
plasma
stabil
maintain
strong
bind
tenascinc
moreov
avidinbind
dna
aptam
modifi
systemat
lna
deriv
demonstr
figur
certain
posit
modifi
aptam
actual
show
improv
bind
affin
kd
valu
nm
unlock
nucleic
acid
una
anoth
modif
ribos
unit
achiev
elimin
singl
bond
sugar
modif
make
aptam
flexibl
structur
flexibl
may
eas
strain
tight
aptam
loop
figur
thrombintarget
dna
underw
una
modif
loop
region
show
increas
thermodynam
stabil
signific
aptam
affin
anticoagul
effici
unlock
nucleic
acid
una
anoth
modif
ribos
unit
achiev
elimin
singl
bond
sugar
modif
make
aptam
flexibl
structur
flexibl
may
eas
strain
tight
aptam
loop
figur
thrombintarget
dna
underw
una
modif
loop
region
show
increas
thermodynam
stabil
signific
aptam
affin
anticoagul
effici
thrombinbind
quadruplex
aptam
unamodifi
thrombinbind
aptam
unamodifi
tba
develop
found
una
substitut
loop
quadruplex
could
increas
bind
affin
clot
time
blood
sampl
una
monom
allow
mani
posit
aptam
without
significantli
chang
thrombinbind
properti
aptam
could
select
lna
una
structur
may
give
better
result
three
differ
lnanucleosid
triphosph
lnattp
lnaatp
test
substrat
kod
dna
polymeras
result
show
kod
dna
polymeras
good
synthesi
dna
oligonucleotid
duplex
contain
lna
nucleotid
effect
presenc
nucleosid
unlock
nucleic
acid
una
lock
nucleic
acid
lna
seri
analog
aptam
effect
prolong
thrombin
time
evalu
kotkowiak
et
al
show
modifi
residu
influenc
thermal
biolog
stabil
gquadruplex
positiondepend
manner
aptam
modifi
simultan
una
lna
possess
twofold
higher
anticoagul
effect
variant
modifi
nucleosid
una
lna
seri
exhibit
prolong
aptam
stabil
human
serum
one
common
aptam
modif
achiev
replac
phosphodiest
linkag
methylphosphon
phosphorothio
figur
thrombinbind
quadruplex
aptam
unamodifi
thrombinbind
aptam
unamodifi
tba
develop
found
una
substitut
loop
quadruplex
could
increas
bind
affin
clot
time
blood
sampl
una
monom
allow
mani
posit
aptam
without
significantli
chang
thrombinbind
properti
aptam
could
select
lna
una
structur
may
give
better
result
three
differ
lnanucleosid
triphosph
lnattp
lnaatp
test
substrat
kod
dna
polymeras
result
show
kod
dna
polymeras
good
synthesi
dna
oligonucleotid
duplex
contain
lna
nucleotid
effect
presenc
nucleosid
unlock
nucleic
acid
una
lock
nucleic
acid
lna
seri
analog
aptam
effect
prolong
thrombin
time
evalu
kotkowiak
et
al
show
modifi
residu
influenc
thermal
biolog
stabil
gquadruplex
positiondepend
manner
aptam
modifi
simultan
una
lna
possess
twofold
higher
anticoagul
effect
variant
modifi
nucleosid
una
lna
seri
exhibit
prolong
aptam
stabil
human
serum
one
common
aptam
modif
achiev
replac
phosphodiest
linkag
methylphosphon
phosphorothio
figur
phosphorothio
modif
might
influenc
thermal
stabil
quadruplex
structur
differ
gquadruplexform
oligonucleotid
phosphorothio
backbon
consid
respons
strongli
bind
inhibit
envelop
protein
hiv
partial
thiophosphoryl
substitut
maximum
thermal
stabil
select
evalu
stabil
condit
nucleas
dnase
hydrolysi
antithrombin
activ
blood
plasma
promis
modifi
oligonucleotid
ggttggtgtggttgg
structur
modifi
tt
loop
retain
thrombinbind
aptam
properti
high
resist
biodegrad
thrombinbind
aptam
ggststsggtgtggststsgg
thiosubstitut
tt
loop
exhibit
similar
antithrombin
effici
compar
unmodifi
one
better
resist
dna
nucleas
blood
serum
abeydeera
et
al
report
phosphorodithio
substitut
singl
nucleotid
rna
aptam
improv
target
bind
affin
stabil
phosphat
backbon
phosphorothio
modif
might
influenc
thermal
stabil
quadruplex
structur
differ
gquadruplexform
oligonucleotid
phosphorothio
backbon
consid
respons
strongli
bind
inhibit
envelop
protein
hiv
partial
thiophosphoryl
substitut
maximum
thermal
stabil
select
evalu
stabil
condit
nucleas
dnase
hydrolysi
antithrombin
activ
blood
plasma
promis
modifi
oligonucleotid
ggttggtgtggttgg
structur
modifi
tt
loop
retain
thrombinbind
aptam
properti
high
resist
biodegrad
thrombinbind
aptam
ggststsggtgtggststsgg
thiosubstitut
tt
loop
exhibit
similar
antithrombin
effici
compar
unmodifi
one
better
resist
postselex
modif
addit
short
phosphorothio
cap
end
aminomodifi
rna
dna
aptam
vpfvegf
show
high
bind
affin
increas
nucleas
resist
mann
et
al
develop
twostep
select
protocol
identifi
thiophosphatemodifi
aptam
eselectin
isol
aptam
show
nucleas
resist
specif
bound
eselectin
high
affin
k
nm
without
recogn
member
selectin
protein
famili
aptam
bound
specif
inflam
tumorassoci
vasculatur
human
carcinoma
deriv
breast
ovari
skin
without
affect
normal
organ
differ
type
phosphorothio
aptam
isol
via
vitro
combinatori
select
exampl
king
et
al
select
purifi
recombin
human
nfkappa
b
protein
rela
duplex
thioaptam
phosphorothio
aptam
show
high
affin
besid
competit
bind
duplex
site
ig
kappa
b
somasunderam
et
al
util
protocol
isol
phosphorothio
aptam
act
inhibitor
rnase
h
domain
revers
transcriptas
high
affin
k
nm
also
separ
monothiophosphatemodifi
aptam
specif
bind
high
affin
rang
nm
affin
significantli
higher
hyaluron
acid
select
thioaptam
target
dengu
viru
envelop
protein
domain
iii
also
achiev
gandham
et
al
thioapatam
bind
ediii
dissoci
constant
nm
recent
thiophosph
ester
aptam
ta
select
larg
combinatori
librari
target
moieti
attach
discoid
silicon
mesopor
microparticl
smp
improv
accumul
carrier
infect
macrophag
lung
thioaptam
significantli
lower
bacteri
load
lung
caus
recruit
lymphocyt
enhanc
bind
affin
specif
protein
well
stabil
vitro
xaptam
next
gener
phosphorothio
aptam
posit
nucleobas
modifi
druglik
function
modif
show
signific
enhanc
nucleas
resist
increas
bind
affin
best
xaptam
modif
small
molecul
drug
antibodi
achiev
molecul
fold
uniqu
structur
scaffold
bind
specif
target
protein
prater
miller
report
singl
methylphosphonateinternucleotid
linkag
end
omethylribonucleotid
figur
show
high
bind
affin
complementari
target
prevent
degrad
exonucleas
activ
found
mammalian
serum
comparison
duplex
stabil
differ
phosphorothio
methylphosphon
rna
analog
two
selfcomplementari
dna
conduct
kiblerherzog
et
al
highli
modifi
phosphorothio
methylphosphon
less
stabl
partial
modifi
counterpart
less
stabl
unmodifi
parent
compound
phosphorothio
deriv
found
stabl
linkag
modifi
adenin
rather
thymin
effect
chemic
modif
thermal
stabil
differ
gquadruplexform
oligonucleotid
investig
sacca
et
al
methylphosphonatemodifi
oligonucleotid
known
thrombinbind
aptam
gave
observ
thermal
transit
result
flat
thermal
profil
contrast
unmodifi
oligonucleotid
phosphorothio
aptam
comparison
duplex
stabil
differ
phosphorothio
methylphosphon
och
rna
analog
two
selfcomplementari
dna
conduct
kiblerherzog
et
al
highli
modifi
phosphorothio
methylphosphon
less
stabl
partial
modifi
counterpart
less
stabl
unmodifi
parent
compound
phosphorothio
deriv
found
stabl
linkag
modifi
adenin
rather
thymin
effect
chemic
modif
thermal
stabil
differ
gquadruplexform
oligonucleotid
investig
sacca
et
al
methylphosphonatemodifi
oligonucleotid
known
thrombinbind
aptam
gave
observ
thermal
transit
result
flat
thermal
profil
contrast
unmodifi
oligonucleotid
phosphorothio
aptam
omethyl
ribonucleotid
analog
gave
revers
concentrationdepend
thermal
transit
addit
loss
neg
charg
level
phosphat
backbon
methylphosphon
analog
lead
strong
destabil
gquadruplex
structur
oligonucleotid
triazol
modif
instead
phosphodiest
linkag
investig
extens
mani
studi
protect
oligonucleotid
nucleas
hydrolysi
modif
usual
achiev
use
click
reaction
azideand
alkynebear
nucleosid
figur
autom
phosphoramidit
synthesi
modifi
dinucleosid
block
figur
triazol
unit
link
nucleotid
directli
methylen
singl
ether
bond
linkag
analog
similar
oligonucleotid
show
increas
resist
nucleas
cleavag
triazol
oligonucleotid
analog
demonstr
dna
bind
affin
similar
unmodifi
oligonucleotid
modif
shown
protect
oligonucleotid
nucleas
hydrolysi
triazolemodifi
dna
aptam
structur
similar
thrombininhibit
gquadruplex
figur
coppercatalys
alkyneazid
cycloaddit
reaction
azid
termin
alkyn
produc
molecul
x
peer
review
figur
coppercatalys
alkyneazid
cycloaddit
reaction
azid
termin
alkyn
produc
triazol
unit
link
nucleotid
directli
methylen
singl
ether
bond
linkag
analog
similar
oligonucleotid
show
increas
resist
nucleas
cleavag
triazol
oligonucleotid
analog
demonstr
dna
bind
affin
similar
unmodifi
oligonucleotid
modif
shown
protect
oligonucleotid
nucleas
hydrolysi
triazolemodifi
dna
aptam
structur
similar
thrombininhibit
gquadruplex
test
stabil
bind
affin
chang
observ
triazol
unit
link
nucleotid
directli
methylen
singl
ether
bond
linkag
analog
similar
oligonucleotid
show
increas
resist
nucleas
cleavag
triazol
oligonucleotid
analog
demonstr
dna
bind
affin
similar
unmodifi
oligonucleotid
modif
shown
protect
oligonucleotid
nucleas
hydrolysi
triazolemodifi
dna
aptam
structur
similar
thrombininhibit
gquadruplex
test
stabil
bind
affin
chang
observ
bind
affin
triazol
modif
protect
aptam
nucleas
hydrolysi
increas
stabil
modifi
posit
nucleic
acid
base
occur
pyrimidin
posit
purin
figur
site
shown
good
contact
polymeras
enzym
easili
adapt
major
groov
nucleic
acid
duplex
modifi
posit
nucleic
acid
base
occur
pyrimidin
posit
purin
figur
site
shown
good
contact
polymeras
enzym
easili
adapt
major
groov
nucleic
acid
duplex
modif
nucleotid
involv
exampl
coupl
lprolinecontain
residu
dipeptid
urea
deriv
sulfamid
residu
follow
triphosphoryl
modifi
triphosph
dntp
shown
excel
substrat
incorpor
dna
polymeras
chain
reaction
pcr
excel
candid
selex
modifi
base
aptam
abl
retain
target
bind
properti
thu
may
enhanc
bind
affin
exampl
basemodifi
aptam
use
instead
thymidin
isol
via
select
experi
human
coagul
proteas
thrombin
figur
chang
effect
increas
chemic
divers
aptam
increas
rate
discoveri
highaffin
ligand
protein
target
also
caus
increas
nucleas
resist
lower
renal
clearanc
hydrophil
side
chain
photoreact
chromophor
incorpor
selex
gener
basemodifi
modif
nucleotid
involv
exampl
coupl
lprolinecontain
residu
dipeptid
urea
deriv
sulfamid
residu
follow
triphosphoryl
modifi
deoxyribonucleosid
triphosph
dntp
shown
excel
substrat
incorpor
dna
polymeras
chain
reaction
pcr
excel
candid
selex
modifi
base
aptam
abl
retain
target
bind
properti
thu
may
enhanc
bind
affin
exampl
basemodifi
aptam
deoxyuridin
use
instead
thymidin
isol
via
select
experi
human
coagul
proteas
thrombin
figur
modifi
posit
nucleic
acid
base
occur
pyrimidin
posit
purin
figur
site
shown
good
contact
polymeras
enzym
easili
adapt
major
groov
nucleic
acid
duplex
modif
nucleotid
involv
exampl
coupl
lprolinecontain
residu
dipeptid
urea
deriv
sulfamid
residu
follow
triphosphoryl
modifi
triphosph
dntp
shown
excel
substrat
incorpor
dna
polymeras
chain
reaction
pcr
excel
candid
selex
modifi
base
aptam
abl
retain
target
bind
properti
thu
may
enhanc
bind
affin
exampl
basemodifi
aptam
use
instead
thymidin
isol
via
select
experi
human
coagul
proteas
thrombin
figur
chang
effect
increas
chemic
divers
aptam
increas
rate
discoveri
highaffin
ligand
protein
target
also
caus
increas
nucleas
resist
gupta
et
al
introduc
differ
chemic
modif
ad
new
side
chain
uracil
side
chain
rang
high
hydrophil
hydrophob
fragment
assess
impact
side
chain
plasma
pharmacokinet
modifi
aptam
chang
effect
increas
chemic
divers
aptam
increas
rate
discoveri
highaffin
ligand
protein
target
also
caus
increas
nucleas
resist
lower
renal
clearanc
hydrophil
side
chain
photoreact
chromophor
incorpor
selex
gener
basemodifi
aptam
high
capabl
coval
interact
rev
protein
antifibrinogen
base
aptam
modifi
boron
triphosph
figur
isol
li
et
al
aptam
specif
recognit
fibrinogen
glycosyl
enhanc
bind
affin
compar
unmodifi
aptam
aptam
specif
recognit
fibrinogen
glycosyl
enhanc
bind
affin
compar
unmodifi
aptam
addit
adenin
residu
posit
uracil
e
n
n
adeninyl
ethyl
carbamylvinyl
uracil
increas
hydrogen
bond
interact
enhanc
effici
target
anticanc
agent
camptothecin
deriv
potent
aptam
select
improv
shorter
aptam
improv
bind
affin
seen
modifi
aptam
compar
natur
aptam
moreov
enantioselect
basemodifi
aptam
isol
selex
capabl
bind
r
isom
thalidomid
aptam
thymidin
replac
modifi
deoxyuridin
cation
group
via
hydrophob
methylen
linker
addit
function
group
improv
stabil
nucleas
increas
bind
affin
thalidomid
argininemodifi
dutp
figur
involv
selex
experi
improv
enantioselect
isol
aptam
display
enantioselect
bind
neg
charg
glutam
acid
target
glycoldna
aptam
produc
alkyn
unit
dutp
via
selma
select
could
recogn
monoclon
antibodi
known
bind
mannoserich
glycan
hiv
envelop
protein
thu
neutral
variou
hiv
strain
lee
colleagu
reveal
nbenzylcarboxyamid
modif
aptam
might
select
increas
target
affin
cancer
cell
signific
addit
adenin
residu
posit
uracil
e
n
n
adeninyl
ethyl
carbamylvinyl
uracil
increas
hydrogen
bond
interact
enhanc
effici
target
anticanc
agent
camptothecin
deriv
potent
aptam
select
improv
shorter
aptam
improv
bind
affin
seen
modifi
aptam
compar
natur
aptam
moreov
enantioselect
basemodifi
aptam
isol
selex
capabl
bind
r
isom
thalidomid
aptam
thymidin
replac
modifi
deoxyuridin
cation
group
via
hydrophob
methylen
linker
addit
function
group
improv
stabil
nucleas
increas
bind
affin
thalidomid
argininemodifi
dutp
figur
involv
selex
experi
improv
enantioselect
isol
aptam
display
enantioselect
bind
neg
charg
glutam
acid
target
aptam
specif
recognit
fibrinogen
glycosyl
enhanc
bind
affin
compar
unmodifi
aptam
addit
adenin
residu
posit
uracil
e
n
n
adeninyl
ethyl
carbamylvinyl
uracil
increas
hydrogen
bond
interact
enhanc
effici
target
anticanc
agent
camptothecin
deriv
potent
aptam
select
improv
shorter
aptam
improv
bind
affin
seen
modifi
aptam
compar
natur
aptam
moreov
enantioselect
basemodifi
aptam
isol
selex
capabl
bind
r
isom
thalidomid
aptam
thymidin
replac
modifi
deoxyuridin
cation
group
via
hydrophob
methylen
linker
addit
function
group
improv
stabil
nucleas
increas
bind
affin
thalidomid
argininemodifi
dutp
figur
involv
selex
experi
improv
enantioselect
isol
aptam
display
enantioselect
bind
neg
charg
glutam
acid
target
glycoldna
aptam
produc
alkyn
unit
dutp
via
selma
select
could
recogn
monoclon
antibodi
known
bind
mannoserich
glycan
hiv
envelop
protein
thu
neutral
variou
hiv
strain
lee
colleagu
reveal
nbenzylcarboxyamid
modif
aptam
might
select
increas
target
affin
cancer
cell
signific
glycoldna
aptam
produc
alkyn
unit
dutp
via
selma
select
could
recogn
monoclon
antibodi
known
bind
mannoserich
glycan
hiv
envelop
protein
thu
neutral
variou
hiv
strain
lee
colleagu
reveal
nbenzylcarboxyamid
modif
aptam
might
select
increas
target
affin
cancer
cell
signific
influenc
normal
healthi
cell
residu
modifi
replac
benzyl
group
aromat
aliphat
group
enhanc
bind
affin
modifi
aptam
target
anoth
increasingli
expand
approach
util
replac
natur
nucleotid
artifici
unnatur
base
dna
sequenc
improv
therapeut
properti
nucleosid
triphosph
modifi
tyrosinelik
phenol
figur
use
select
dna
aptam
escherichia
coli
cell
modifi
aptam
display
high
select
affin
target
cell
compar
unmodifi
aptam
influenc
normal
healthi
cell
residu
modifi
replac
benzyl
group
aromat
aliphat
group
enhanc
bind
affin
modifi
aptam
target
anoth
increasingli
expand
approach
util
replac
natur
nucleotid
artifici
unnatur
base
dna
sequenc
improv
therapeut
properti
nucleosid
triphosph
modifi
tyrosinelik
phenol
figur
use
select
dna
aptam
escherichia
coli
cell
modifi
aptam
display
high
select
affin
target
cell
compar
unmodifi
aptam
new
protocol
late
describ
select
nucleobasemodifi
aptam
protocol
util
click
chemistri
cuaac
introduc
favor
nucleobas
modif
base
alkynemodifi
uridin
influenc
normal
healthi
cell
residu
modifi
replac
benzyl
group
aromat
aliphat
group
enhanc
bind
affin
modifi
aptam
target
anoth
increasingli
expand
approach
util
replac
natur
nucleotid
artifici
unnatur
base
dna
sequenc
improv
therapeut
properti
nucleosid
triphosph
modifi
tyrosinelik
phenol
figur
use
select
dna
aptam
escherichia
coli
cell
modifi
aptam
display
high
select
affin
target
cell
compar
unmodifi
aptam
new
protocol
late
describ
select
nucleobasemodifi
aptam
protocol
util
click
chemistri
cuaac
introduc
favor
nucleobas
modif
base
alkynemodifi
uridin
new
protocol
late
describ
select
nucleobasemodifi
aptam
protocol
util
click
chemistri
cuaac
introduc
favor
nucleobas
modif
base
alkynemodifi
uridin
edu
instead
thymidin
new
protocol
enabl
wide
rang
function
gener
modifi
dna
aptam
extend
interact
properti
slow
offratemodifi
aptam
somam
aptam
signific
base
modif
give
proteinlik
function
formul
improv
bind
affin
bind
kinet
enhanc
select
compar
tradit
aptam
achiev
increas
number
strength
hydrophob
interact
nucleic
acid
correspond
target
thu
partial
mimick
bind
mode
antibodi
protein
power
kind
base
modif
exhibit
littl
nucleas
degrad
incub
human
serum
facilit
detect
variou
protein
blood
serum
wide
appli
discoveri
diseas
biomark
modifi
dna
somam
nbenzylcarboxamid
deoxyuridin
bndu
n
carboxamid
deoxyuridin
napdu
replac
dt
inhibit
signal
key
compon
inflammatori
diseas
found
stabl
serum
block
interact
receptor
advanc
somamerbas
assay
develop
quantif
solubl
hepatocellular
carcinoma
hcc
patient
sampl
use
somam
assay
verifi
good
sensit
accuraci
precis
compar
tradit
antibodybas
assay
high
bind
affin
gawand
cowork
explor
select
experi
use
doublemodifi
dna
aptam
aminoacidlik
moieti
pyrimidin
base
target
proprotein
convertas
subtilisinkexin
type
isol
aptam
show
higher
affin
biostabl
inhibitori
potenc
compar
singli
modifi
aptam
broad
util
research
diagnost
therapeut
applic
wang
et
al
report
biophys
enzymat
properti
studi
three
wide
use
proteinlik
side
chain
dntp
daimtp
dugatp
dcaatp
basepair
abil
oligonucleotid
one
three
modifi
nucleosid
test
thermal
denatur
analysi
substrat
enzymat
polymer
modifi
natur
dntp
spiegelm
synthet
mirror
imag
dnucleic
acid
show
high
resist
nucleas
degrad
may
retain
bind
affin
dform
target
select
high
bind
affin
new
target
figur
exampl
structur
mirror
imag
rna
oligonucleotid
lconfigur
neutral
stromal
cellderiv
interfer
chronic
lymphocyt
leukemia
migrat
drug
resist
spiegelm
bind
neutral
develop
interfer
tumor
microenviron
cell
mobil
lrna
aptam
target
transactiv
respons
tar
rna
develop
spiegelm
show
great
specif
strong
bind
activ
base
tertiari
interact
watsoncrick
pair
addit
mix
dnarna
mirror
imag
aptam
bind
glucagon
improv
glucos
toler
model
type
type
diabet
lenantiomer
spiegelm
gonadotropinreleas
hormon
gnrh
select
random
pool
oligonucleotid
effect
antagonist
spiegelm
show
high
bind
affin
k
nm
longer
plasma
halflif
stabil
anoth
lgnrh
spiegelm
chemic
synthes
accord
isol
natur
dgnrh
aptam
result
spiegelm
similar
affin
daptam
biolog
stabl
mirror
imag
enantiomer
ldna
spiegelm
bacteri
staphylococc
enterotoxin
b
develop
spiegelm
bound
whole
protein
target
slightli
reduc
affin
show
possibl
identifi
spiegelm
larg
protein
target
spiegelm
also
undergo
similar
differ
strategi
chemic
modif
natur
aptam
enhanc
stabil
nucleas
improv
bind
affin
nucleaseresist
modifi
lrna
aptam
mlra
cation
nucleotid
aminoallyluridin
isol
vitro
select
process
spiegelm
capabl
bind
oncogen
except
affin
cation
modif
absolut
crucial
bind
lrna
aptam
target
transactiv
respons
tar
rna
develop
spiegelm
show
great
specif
strong
bind
activ
base
tertiari
interact
watsoncrick
pair
addit
mix
dnarna
mirror
imag
aptam
bind
glucagon
improv
glucos
toler
model
type
type
diabet
lenantiomer
spiegelm
gonadotropinreleas
hormon
gnrh
select
random
pool
oligonucleotid
effect
antagonist
spiegelm
show
high
bind
affin
kd
nm
longer
plasma
halflif
stabil
anoth
lgnrh
spiegelm
chemic
synthes
accord
isol
natur
dgnrh
aptam
result
spiegelm
similar
affin
daptam
biolog
stabl
mirror
imag
enantiomer
ldna
spiegelm
bacteri
staphylococc
enterotoxin
b
develop
spiegelm
bound
whole
protein
target
slightli
reduc
affin
show
possibl
identifi
spiegelm
larg
protein
target
spiegelm
also
undergo
similar
differ
strategi
chemic
modif
natur
aptam
enhanc
stabil
nucleas
improv
bind
affin
nucleaseresist
modifi
lrna
aptam
mlra
cation
nucleotid
aminoallyluridin
isol
vitro
select
process
spiegelm
capabl
bind
oncogen
except
affin
cation
modif
absolut
crucial
bind
final
taylor
hollig
describ
protocol
replic
artifici
analog
dna
rna
differ
backbon
sugar
homolog
xeno
nucleic
acid
xna
direct
evolut
synthet
oligonucleotid
ligand
xna
aptam
specif
target
protein
nucleic
acid
unit
crosschemistri
select
exponenti
enrich
xselex
approach
use
approach
may
appli
select
isol
fulli
modifi
xna
aptam
wide
rang
target
molecul
convent
selex
base
four
natur
dnarna
nucleotid
often
yield
poor
binder
synthet
biolog
increas
number
dnarna
build
block
tool
sequenc
pcr
amplifi
clone
artifici
expand
genet
inform
system
aegiss
sever
exampl
report
selex
use
aegi
produc
molecul
bind
cancer
cell
function
rna
molecul
contain
artifici
nucleobas
pair
design
hernandez
et
al
increas
number
build
block
nucleic
acidsthey
replac
c
g
pair
pair
two
compon
artifici
expand
geneticinform
system
aegi
z
p
pyridon
one
structur
show
z
p
pair
final
taylor
hollig
describ
protocol
replic
artifici
analog
dna
rna
differ
backbon
sugar
homolog
xeno
nucleic
acid
xna
direct
evolut
synthet
oligonucleotid
ligand
xna
aptam
specif
target
protein
nucleic
acid
unit
crosschemistri
select
exponenti
enrich
xselex
approach
use
approach
may
appli
select
isol
fulli
modifi
xna
aptam
wide
rang
target
molecul
convent
selex
base
four
natur
dnarna
nucleotid
often
yield
poor
binder
synthet
biolog
increas
number
dnarna
build
block
tool
sequenc
pcr
amplifi
clone
artifici
expand
genet
inform
system
aegiss
sever
exampl
report
selex
use
aegi
produc
molecul
bind
cancer
cell
function
rna
molecul
contain
artifici
nucleobas
pair
design
hernandez
et
al
increas
number
build
block
nucleic
acidsthey
replac
c
g
pair
pair
two
compon
artifici
expand
geneticinform
system
aegi
z
p
pyridon
one
structur
show
z
p
pair
greatli
chang
conform
rna
molecul
detail
interact
hypoxanthin
ligand
nm
affin
riboswitch
guanin
laboratori
vitro
evolut
live
experi
base
artifici
expand
genet
inform
system
aegi
report
biondi
et
al
aegi
aptam
bind
isol
protein
target
outlin
antigen
bacillu
anthraci
aegi
aptam
show
improv
stabil
bind
aptam
target
major
nucleic
acid
degrad
caus
plasma
exonucleas
break
phosphodiest
bond
either
termin
lead
cleavag
nucleotid
one
time
chemic
modif
termin
increas
stabil
howev
cycliz
elimin
sourc
degrad
entir
exampl
comparison
two
linear
aptam
target
distinct
doubl
strand
circular
aptam
show
signific
biostabl
circular
one
circular
bival
aptam
cb
aptam
construct
aptam
select
live
cancer
cell
test
nucleas
stabil
bind
affin
vivo
thermal
stabil
result
show
circular
aptam
sustain
sequenc
integr
h
compar
h
linear
aptam
biolog
media
addit
thermal
stabil
enhanc
least
c
anoth
exampl
cyclic
thrombinbind
aptam
cyctba
prepar
coval
bond
end
linear
aptam
via
linker
thermal
stabil
cyctba
highli
enhanc
increas
melt
point
c
k
na
ion
environ
increas
halflif
pb
strong
indic
cyctba
higher
resist
toward
nucleas
howev
anticoagul
activ
drop
half
drop
activ
indic
need
flexibl
aptam
structur
mention
increas
aptam
affin
target
stabil
main
hurdl
aptam
applic
especi
therapeut
sever
chemic
modif
increas
stabil
via
increas
size
mass
aptam
promis
howev
might
affect
affin
toward
target
multival
aptam
might
solut
sinc
increas
size
time
increas
affin
multival
aptam
construct
compos
two
dimer
multi
ident
differ
aptam
motif
without
addit
structur
element
simpli
connect
ident
aptam
increas
affin
target
sinc
increas
number
contact
point
connect
differ
aptam
also
lead
increas
versatil
refin
aptam
need
achiev
desir
affin
dimer
aptam
ident
differ
perform
hasegawa
cowork
dimer
two
aptam
thrombin
bind
differ
site
use
thymin
linker
variabl
length
prove
enhanc
affin
compar
monom
addit
improv
thrombininhibit
effect
also
test
dimer
two
ident
aptam
vascular
epitheli
growth
factor
vegf
dimer
protein
ligandguid
select
lig
aptam
known
give
aptam
high
specif
howev
aptam
suffer
low
affin
hinder
applic
diagnost
therapeut
exampl
ligsaptam
membran
igm
migm
introduc
high
specif
order
improv
affin
dimer
aptam
prepar
show
enhanc
affin
without
affect
specif
multival
enhanc
affin
stabil
aptam
also
improv
cellular
uptak
multival
dna
structur
dual
aptam
guanosinerich
oligonucleotid
aptam
develop
target
nucleolinoverexpress
cell
aptam
develop
target
mucin
glycoprotein
show
superior
intercellular
uptak
compar
oligom
singl
type
aptam
extens
effort
dedic
develop
fluoresc
rna
aptam
crucial
facilit
livecel
imag
fluoresc
rna
develop
howev
aptam
suffer
poor
bright
photost
dimer
aptam
ocor
prepar
test
show
high
affin
bright
stabil
compar
parent
aptam
nanoparticl
function
differ
type
aptam
target
ligand
function
achiev
via
variou
approach
without
affect
aptam
function
chemic
coval
bond
physic
conjug
strategi
frequent
use
spacer
linker
maintain
aptam
bind
activ
direct
aptam
conjug
nanoparticl
formul
usual
done
certain
modif
aptam
structur
exampl
aptam
call
select
specif
ramo
cell
bcell
lymphoma
cell
line
incorpor
micel
construct
attach
simpl
lipid
tail
phosphoramidit
diacyl
chain
onto
end
aptam
insert
peg
linker
amphiphil
unit
selfassembl
spheric
micel
structur
result
show
higher
intern
ramos
cell
compar
unconjug
micel
direct
conjug
also
use
antinucleolinspecif
dna
ncl
aptam
xing
et
al
studi
function
surfac
doxorubicinload
liposom
aptam
firstli
bound
cholesterol
molecul
polythymin
spacer
involv
liposom
bilay
structur
liposom
prepar
figur
similarli
aptam
direct
conjug
use
coat
liposom
load
cisplatin
chemic
coval
bond
physic
conjug
strategi
frequent
use
spacer
linker
maintain
aptam
bind
activ
direct
aptam
conjug
nanoparticl
formul
usual
done
certain
modif
aptam
structur
exampl
aptam
call
select
specif
ramo
cell
bcell
lymphoma
cell
line
incorpor
micel
construct
attach
simpl
lipid
tail
phosphoramidit
diacyl
chain
onto
end
aptam
insert
peg
linker
amphiphil
unit
selfassembl
spheric
micel
structur
result
show
higher
intern
ramos
cell
compar
unconjug
micel
direct
conjug
also
use
antinucleolinspecif
dna
ncl
aptam
xing
et
al
studi
function
surfac
doxorubicinload
liposom
aptam
firstli
bound
cholesterol
molecul
polythymin
spacer
involv
liposom
bilay
structur
liposom
prepar
figur
similarli
aptam
direct
conjug
use
coat
liposom
load
cisplatin
riccardi
et
al
design
highli
integr
multifunct
nanosystem
base
niosom
formul
niosom
load
nucleolipid
ru
iii
complex
hothyru
decor
aptam
via
postinsert
dispers
method
niosom
formul
show
increas
antiprolif
activ
load
ru
iii
complex
aptam
compar
test
control
valuabl
therapeut
window
found
hela
cancer
cell
concentr
final
formul
provid
sever
medic
applic
includ
ondemand
releas
specif
tissuecel
type
target
vivo
imag
diagnosi
aptam
also
directli
incorpor
nanoparticl
formul
exampl
gadoliniumdop
luminesc
mesopor
strontium
hydroxyapatit
nanorod
load
doxorubicin
gd
srhapdox
coat
aptam
coat
perform
fridg
incub
preform
drugload
nanorod
g
quadruplex
structur
aptam
h
mainli
strong
electrostat
forc
aptamercap
gd
srhapnanorod
intern
cell
result
pore
open
drug
releas
riccardi
et
al
design
highli
integr
multifunct
nanosystem
base
niosom
formul
niosom
load
nucleolipid
ru
iii
complex
hothyru
decor
aptam
via
postinsert
dispers
method
niosom
formul
show
increas
antiprolif
activ
load
ru
iii
complex
aptam
compar
test
control
valuabl
therapeut
window
found
hela
cancer
cell
concentr
final
formul
provid
sever
medic
applic
includ
ondemand
releas
specif
tissuecel
type
target
vivo
imag
diagnosi
aptam
also
directli
incorpor
nanoparticl
formul
exampl
gadoliniumdop
luminesc
mesopor
strontium
hydroxyapatit
nanorod
load
doxorubicin
gd
srhapdox
coat
aptam
coat
perform
fridg
incub
preform
drugload
nanorod
g
quadruplex
structur
aptam
h
mainli
strong
electrostat
forc
aptamercap
gd
srhapnanorod
intern
cell
result
pore
open
drug
releas
postinsert
mostli
use
function
preform
liposom
certain
aptam
link
lipid
anchor
dspepeg
form
micel
figur
willi
et
al
function
membran
lipid
vesicl
nucleasest
antivegf
aptam
use
diacylglycerol
dag
lipid
anchor
conjug
influenc
bind
affin
aptam
plasma
resid
time
liposomeanchor
aptam
consider
improv
compar
free
aptam
carbodiimid
frequent
use
organ
synthesi
bioconjug
drug
deliveri
exampl
watersolubl
carbodiimid
dimethylaminopropyl
carbodiimid
edc
common
reagent
use
activ
carboxyl
acid
residu
react
ligand
contain
amino
group
result
amid
bond
linkag
figur
mann
et
al
function
liposom
oligonucleotid
aptam
thioaptam
eselectin
esta
use
carbodiimid
chemistri
carboxyl
unlabel
esta
conjug
amino
pegyl
stealth
liposom
use
hydrochlorid
edc
sulfo
nhydroxysuccinimid
sulfonh
vitro
target
studi
verifi
effici
rapid
uptak
estaconjug
liposom
estalip
moreov
aptamerliposom
retain
human
breast
tumor
xenograft
model
without
decreas
circul
halflif
aptamermodifi
thermosensit
liposom
tsl
design
effici
magnet
reson
imag
mri
probe
zhang
et
al
encapsul
gdchelat
optim
tsl
formul
follow
conjug
specif
target
tumor
cell
overexpress
nucleolin
receptor
tsl
structur
includ
carboxyl
aptam
conjug
onto
tsl
edcnh
carbodiimid
chemistri
result
liposom
exhibit
much
higher
relax
cell
enhanc
earli
cancer
diagnosi
phsensit
polymer
micel
use
polyethylen
glycolblockpoli
ester
tpgsbpbae
tp
phsensit
copolym
load
paclitaxel
ptx
function
surfac
develop
zhang
et
al
aptam
conjug
achiev
carbodiimid
chemistri
tpg
polym
treat
succin
anhydrid
obtain
carboxylmodifi
tpg
polym
aminemodifi
aptam
ad
edcnhsactiv
tpg
polym
higher
cellular
uptak
signific
cytotox
reduct
tumor
growth
myelosuppress
observ
vitro
vivo
mice
ovarian
cancer
cell
compar
free
ptx
inject
anoth
similar
exampl
polymer
aptam
function
base
carbodiimid
chemistri
use
design
multifunct
composit
micel
made
poloxam
pluron
betacyclodextrinlink
poli
lactid
copoli
ethylen
glycol
plapeg
encapsul
doxorubicin
aptam
pluron
pluron
synthes
reaction
carboxylatedpluron
amino
group
end
aptam
vivo
studi
tumorbear
mice
demonstr
composit
micel
show
increas
blood
circul
enhanc
accumul
tumor
improv
anticanc
activ
decreas
cardiotox
moreov
carbodiimid
protocol
aptam
conjug
adapt
develop
doxorubicinload
unimolecular
micel
compos
hyperbranch
copolym
molecul
plapeg
polym
antipsma
aptam
cover
moreov
aptamerliposom
retain
human
breast
tumor
xenograft
model
without
decreas
circul
halflif
aptamermodifi
thermosensit
liposom
tsl
design
effici
magnet
reson
imag
mri
probe
zhang
et
al
encapsul
gdchelat
optim
tsl
formul
follow
conjug
specif
target
tumor
cell
overexpress
nucleolin
receptor
tsl
structur
includ
carboxyl
aptam
conjug
onto
tsl
edcnh
carbodiimid
chemistri
result
liposom
exhibit
much
higher
relax
cell
enhanc
earli
cancer
diagnosi
phsensit
polymer
micel
use
polyethylen
glycolblockpoli
ester
tpgsbpbae
tp
phsensit
copolym
load
paclitaxel
ptx
function
surfac
develop
zhang
et
al
aptam
conjug
achiev
carbodiimid
chemistri
tpg
polym
treat
succin
anhydrid
obtain
carboxylmodifi
tpg
polym
aminemodifi
aptam
ad
edcnhsactiv
tpg
polym
higher
cellular
uptak
signific
cytotox
reduct
tumor
growth
myelosuppress
observ
vitro
vivo
mice
ovarian
cancer
cell
compar
free
ptx
inject
anoth
similar
exampl
polymer
aptam
function
base
carbodiimid
chemistri
use
design
multifunct
composit
micel
made
poloxam
pluron
betacyclodextrinlink
poli
lactid
copoli
ethylen
glycol
plapeg
encapsul
doxorubicin
aptam
pluron
pluron
synthes
reaction
carboxylatedpluron
amino
group
end
aptam
vivo
studi
tumorbear
mice
demonstr
composit
micel
show
increas
blood
circul
enhanc
accumul
tumor
improv
anticanc
activ
decreas
cardiotox
moreov
carbodiimid
protocol
aptam
conjug
adapt
develop
doxorubicinload
unimolecular
micel
compos
hyperbranch
copolym
molecul
plapeg
polym
antipsma
aptam
cover
surfac
formul
show
higher
level
dox
accumul
tumor
tissu
compar
aptamerfre
polymer
micel
polymer
nanocarri
compos
mainli
synthet
polym
polyest
cation
polym
well
natur
polym
polysaccharid
protein
albumin
collagen
also
function
aptam
carbodiimid
chemistri
achiev
carboxyl
function
hydrophil
part
polymer
unit
peg
carboxyl
group
nanoparticl
surfac
make
avail
surfac
carbodiimid
coupl
aminoaptam
exampl
carboxytermin
poli
llacticcoglycol
acid
blockpoli
ethylen
glycol
plgabpegcooh
polym
nanoparticl
conjug
rna
aptam
apt
bind
prostatespecif
membran
antigen
psma
formul
evalu
lncap
psma
xenograft
mous
model
prostat
cancer
nonaggreg
polymer
nanoconjug
paclitaxelpolylactid
ptxlpla
prepar
pla
function
pegcooh
obtain
plapegcooh
bioconjug
aminetermin
aptam
carbodiimid
coupl
reaction
presenc
edc
nh
give
nanoconjug
aptamernanoconjug
found
abl
effect
target
prostatespecif
membran
antigen
cellspecif
manner
carbodiimid
coupl
chemistri
plapegcooh
copolym
amino
terminalaptam
also
appli
decor
docetaxel
dtxl
encapsul
nanoparticl
formul
biocompat
biodegrad
plgabpeg
copolym
fluoropyrimidin
rna
aptam
distinguish
extracellular
domain
prostatespecif
membran
antigen
psma
carbodiimid
bioconjug
approach
aptam
function
surfac
plgabpegcoohbas
nanoparticl
develop
target
drug
deliveri
system
antincl
aptam
aptam
epitheli
cell
adhes
molecul
epcam
paclitaxeltarget
deliveri
glioma
paclitaxeltarget
deliveri
breast
cancer
curcuminand
deliveri
colorect
adenocarcinoma
respect
figur
alibolandi
et
al
adapt
approach
synthes
plgabpeg
nanoparticl
load
doxorubicin
figur
follow
antiepcam
aptam
function
similar
coupl
chemistri
show
higher
tumor
inhibit
mous
xenograft
model
human
small
lung
cancer
compar
nonaptamerconjug
polymer
nanoparticl
plgabpeg
nanoparticl
encapsul
salinomycin
also
decor
target
rna
aptam
bind
marker
base
carbodiimid
coupl
chemistri
higher
cytotox
toward
osteosarcoma
cancer
stem
cell
shown
compar
nonfunction
nanoparticl
aptamertag
plgalecithinpeg
nanoparticl
load
paclitaxel
tumor
cell
target
deliveri
test
aravind
et
al
function
plgalecithinpeg
nanoparticl
exhibit
high
encapsul
effici
superior
sustain
drug
releas
compar
drug
load
plain
plga
nanoparticl
consid
potenti
carrier
candid
differenti
target
drug
deliveri
treat
adenocarcinoma
chitosanbas
polymer
nanocarri
irinotecan
metabolit
target
aptam
via
carbodiimid
chemistri
edcnh
techniqu
perform
aptamerguid
nanocarri
show
enhanc
cytotox
compar
nontarget
nanocarri
amino
terminalaptam
also
appli
decor
docetaxel
dtxl
encapsul
nanoparticl
formul
biocompat
biodegrad
plgabpeg
copolym
rna
aptam
distinguish
extracellular
domain
prostatespecif
membran
antigen
psma
carbodiimid
bioconjug
approach
aptam
function
surfac
plgabpegcoohbas
nanoparticl
develop
target
drug
deliveri
system
antincl
aptam
aptam
epitheli
cell
adhes
molecul
epcam
paclitaxeltarget
deliveri
glioma
paclitaxeltarget
deliveri
breast
cancer
curcuminand
deliveri
colorect
adenocarcinoma
respect
figur
plgabpeg
nanoparticl
encapsul
salinomycin
also
decor
target
rna
aptam
bind
marker
base
carbodiimid
coupl
chemistri
higher
cytotox
toward
osteosarcoma
cancer
stem
cell
shown
compar
nonfunction
nanoparticl
aptamertag
plgalecithinpeg
nanoparticl
load
paclitaxel
tumor
cell
target
deliveri
test
aravind
et
al
function
plgalecithinpeg
nanoparticl
exhibit
high
encapsul
effici
superior
sustain
drug
releas
compar
drug
load
plain
plga
nanoparticl
consid
potenti
carrier
candid
differenti
target
drug
deliveri
treat
adenocarcinoma
chitosanbas
polymer
nanocarri
irinotecan
metabolit
target
aptam
via
carbodiimid
chemistri
edcnh
techniqu
perform
aptamerguid
nanocarri
show
enhanc
cytotox
compar
nontarget
nanocarri
aptamerag
nanoclust
conjug
polyethylen
glycolco
ultrasmal
aptamerag
nanoclust
conjug
polyethylen
glycolco
ultrasmal
gadolinium
oxid
nanoparticl
peggd
np
coval
linkag
carboxyl
group
peg
amino
group
modifi
aptam
trackingimag
nanoparticl
induc
hyperthermia
target
cancer
cell
line
carbodiimid
coupl
chemistri
also
appli
conjug
aptam
quantum
dot
qd
nanoparticl
carboxyl
coreshel
cdsezn
qd
first
activ
edcnh
reagent
result
nhydroxysuccinimideactiv
qd
coval
link
nh
modifi
psma
aptam
doxorubicin
intercal
doublestrand
stem
aptam
qdapt
dox
multifunct
nanosystem
deliv
dox
target
prostat
cancer
cell
sens
deliveri
dox
activ
fluoresc
qd
similar
conjug
chemistri
adapt
design
tumortarget
phrespons
quantum
aptamerdoxorubicin
conjug
chemotherapi
ovarian
cancer
shown
develop
aptamerguid
conjug
higher
cytotox
free
dox
multidrugresist
cancer
cell
figur
tumortarget
phrespons
quantum
aptamerdoxorubicin
conjug
chemotherapi
ovarian
cancer
shown
develop
aptamerguid
conjug
higher
cytotox
free
dox
multidrugresist
cancer
cell
figur
aptam
use
crosslink
carboxylfunction
silica
nanoparticl
coohfsinp
edcnh
carbodiimid
chemistri
aptamerconjug
rubpydop
silica
nanoparticl
test
human
breast
carcinoma
cell
label
dyedop
silica
nanoparticl
serv
stabl
bioprob
facil
conjug
desir
biomolecul
psma
aptam
also
conjug
surfac
carboxylmodifi
superparamagnet
iron
oxid
nanoparticl
via
carbodiimid
chemistri
doxorubicin
intercal
within
aptam
gc
pair
nanocomposit
combin
show
higher
toxic
target
cell
minim
side
effect
nontarget
cell
aptam
coval
link
edcnhsactiv
nanoclust
compos
mesopor
metalorgan
framework
mof
shell
upconvers
luminesc
core
ucnp
target
nanoclust
intercal
doxorubicin
form
multifunct
nanosystem
interven
drug
deliveri
cell
imag
new
materi
incorpor
gold
nanorod
mesopor
silica
structur
surfac
modifi
dna
aptam
construct
nanostructur
function
carboxyl
group
use
succin
anhydrid
subsequ
aptamerg
nanovehicl
decor
bind
aminemodifi
aptam
use
edcnh
carbodiimid
chemistri
multifunct
nanostructur
combin
chemotherapi
photochemotherapi
imag
one
system
standard
peptid
bond
format
methodolog
use
edcnh
coupl
chemistri
also
use
conjug
aminomodifi
antiprotein
tyrosin
kinas
aptam
aptam
aptam
surfac
carboxylfreemodifi
porou
hollow
magnetit
nanoparticl
phmnp
load
doxorubicin
multifunct
nanosystem
test
target
cancer
chemotherapi
magnet
reson
imag
mri
aminemodifi
aptam
use
crosslink
carboxylfunction
silica
nanoparticl
coohfsinp
edcnh
carbodiimid
chemistri
aptamerconjug
rubpydop
silica
nanoparticl
test
human
breast
carcinoma
cell
label
dyedop
silica
nanoparticl
serv
stabl
bioprob
facil
conjug
desir
biomolecul
psma
aptam
also
conjug
surfac
carboxylmodifi
superparamagnet
iron
oxid
nanoparticl
via
carbodiimid
chemistri
doxorubicin
intercal
within
aptam
gc
pair
nanocomposit
combin
show
higher
toxic
target
cell
minim
side
effect
nontarget
cell
nh
modifi
aptam
coval
link
edcnhsactiv
nanoclust
compos
mesopor
metalorgan
framework
mof
shell
upconvers
luminesc
core
ucnp
target
nanoclust
intercal
doxorubicin
form
ucnp
multifunct
nanosystem
interven
drug
deliveri
cell
imag
new
materi
incorpor
gold
nanorod
mesopor
silica
structur
surfac
modifi
dna
aptam
construct
nanostructur
function
carboxyl
group
use
succin
anhydrid
subsequ
aptamerg
nanovehicl
decor
bind
aminemodifi
aptam
use
edcnh
carbodiimid
chemistri
multifunct
nanostructur
combin
chemotherapi
photochemotherapi
imag
one
system
standard
peptid
bond
format
methodolog
use
edcnh
coupl
chemistri
also
use
conjug
aminomodifi
antiprotein
tyrosin
kinas
aptam
aptam
aptam
surfac
carboxylfreemodifi
porou
hollow
magnetit
nanoparticl
phmnp
load
doxorubicin
multifunct
nanosystem
test
target
cancer
chemotherapi
magnet
reson
imag
mri
thiol
maleimid
coupl
chemistri
michael
addit
thiol
maleimid
michael
accept
commonli
use
bioconjug
thiolat
sh
drug
target
ligand
macromolecul
surfac
nanoparticl
drug
deliveri
system
figur
thiol
maleimid
coupl
chemistri
michael
addit
thiol
maleimid
michael
accept
commonli
use
bioconjug
thiolat
sh
drug
target
ligand
macromolecul
surfac
nanoparticl
drug
deliveri
system
figur
dna
aptam
success
attach
surfac
liposom
use
thiolmaleimid
chemistri
prepar
aptamerliposom
maleimid
polyethyleneglycol
pegmal
incorpor
liposom
membran
prepar
follow
overnight
incub
c
aptam
aptamerliposom
cellular
uptak
studi
demonstr
target
critic
cellular
uptak
dna
aptam
select
mous
tumor
endotheli
cell
antimtec
aptam
aptam
function
surfac
pegyl
liposom
use
thiolmaleimid
crosslink
function
indic
potenti
target
deliveri
antiangiogenesi
drug
tumor
endotheli
cell
figur
dna
aptam
success
attach
surfac
liposom
use
thiolmaleimid
chemistri
prepar
aptamerliposom
maleimid
polyethyleneglycol
pegmal
incorpor
liposom
membran
liposom
prepar
follow
overnight
incub
c
aptam
aptamerliposom
cellular
uptak
studi
demonstr
target
critic
cellular
uptak
dna
aptam
select
mous
tumor
endotheli
cell
antimtec
aptam
aptam
function
surfac
pegyl
liposom
use
thiolmaleimid
crosslink
function
indic
potenti
target
deliveri
antiangiogenesi
drug
tumor
endotheli
cell
figur
thiol
maleimid
coupl
chemistri
michael
addit
thiol
maleimid
michael
accept
commonli
use
bioconjug
thiolat
sh
drug
target
ligand
macromolecul
surfac
nanoparticl
drug
deliveri
system
figur
dna
aptam
success
attach
surfac
liposom
use
thiolmaleimid
chemistri
prepar
aptamerliposom
maleimid
polyethyleneglycol
pegmal
incorpor
liposom
membran
prepar
follow
overnight
incub
c
aptam
aptamerliposom
cellular
uptak
studi
demonstr
target
critic
cellular
uptak
dna
aptam
select
mous
tumor
endotheli
cell
antimtec
aptam
aptam
function
surfac
pegyl
liposom
use
thiolmaleimid
crosslink
function
indic
potenti
target
deliveri
antiangiogenesi
drug
tumor
endotheli
cell
figur
li
et
al
develop
nucleolintarget
liposom
guid
aptam
deliv
antibraf
sirna
sibraf
treatment
malign
melanoma
aptam
coval
attach
sirnaload
lipoplex
via
thiolmaleimid
chemistri
combin
show
major
silenc
activ
tumor
xenograft
mice
inhibit
melanoma
growth
rna
aptam
receptor
select
conjug
surfac
pegyl
liposom
use
thiolmaleimid
chemistri
liposom
show
higher
select
uptak
cancer
cell
line
compar
cell
line
moreov
thiolat
conjug
dspepegmaleimid
use
thiolmaleimid
chemistri
follow
success
postinsert
liposom
done
alshaer
et
al
micel
compos
dspepeg
dspepegmaleimid
prepar
thin
film
evapor
hydrat
method
conjug
micelledspepegm
perform
use
thiolmaleimid
crosslink
reaction
form
thioether
bond
postinsert
sirnaload
liposom
mix
incub
c
h
nanocarri
show
higher
inhibit
liposom
vitro
prolong
gene
inhibit
vivo
orthotop
breast
cancer
model
thiolmaleimid
postinsert
protocol
also
adapt
thermosensit
liposom
encapsul
doxorubicin
ammonium
bicarbon
select
target
multidrugresist
breast
cancer
cell
overexpress
nucleolin
dendrim
also
guid
aptam
dendrim
synthet
highli
branch
treelik
macromolecul
nanometr
dimens
dendrim
mani
function
group
surfac
offer
high
number
site
conjug
target
ligand
gene
deliveri
system
compos
polyamidoamin
pamam
dendrim
function
surfac
pegmal
via
specif
reaction
primari
amino
group
pamam
nh
group
bifunct
peg
deriv
result
conjug
pamampegm
bioconjug
shmodifi
second
gener
antipsma
aptam
via
thiolmaleimid
chemistri
target
nanoformul
load
tumor
suppressor
noncod
gene
induc
apoptosi
select
cell
death
prostat
cancer
cell
parallel
chemistri
thiolmaleimid
conjug
use
introduc
soft
electrophil
michael
system
surfac
nanoparticl
approach
use
dendrim
nanoparticl
due
versatil
surfac
function
group
antinucleolin
aptam
conjug
amphiphil
multimolecular
hyperbranch
dendrit
polym
use
techniqu
target
system
enhanc
cell
uptak
excel
fluoresc
properti
smart
target
capabl
vitro
indic
great
potenti
promis
carrier
bioimag
cancerspecif
deliveri
anoth
thiolmaleimiderel
aptam
coupl
use
conjug
epcam
aptam
carboxymethyl
cellulos
cmc
magnet
iron
oxid
nanoparticl
cmcmnp
cmcmnp
interact
via
carbodiimid
coupl
order
introduc
amino
group
cmcmnp
surfac
next
thiolat
epcam
aptam
coval
link
aminofunction
cmcmnp
use
heterobifunct
crosslink
acidnh
ester
magnet
nanoparticleaptam
probe
util
specif
hepatocellular
carcinoma
imag
treatment
propionyl
hydrazid
pdph
altern
aptam
bioconjug
crosslink
pdph
heterofunct
crosslink
possess
carbonylreact
hydrazid
group
one
end
sulfhydrylreactivepyridyl
disulfid
group
end
studi
pala
et
al
dextranco
ferric
oxid
magnet
nanocarri
conjug
aptam
develop
induc
hyperthermia
mg
cell
hydrazid
group
firstli
react
dextrin
moieti
form
hydrazon
bond
follow
conjug
thiolat
aptam
pyridyl
end
form
disulfid
bond
aptamertag
nanoparticl
highli
specif
toward
cell
lower
dose
requir
kill
target
cell
compar
aptamerfre
nanoparticl
aptam
also
attach
silicacarbon
nanoparticl
load
doxorubicin
chemophototherm
therapi
breast
cancer
cell
line
prepar
aptamerfunction
mesopor
silicacarbonbas
doxorubicin
carri
bring
peg
serv
linker
aminefunction
mscn
thiol
groupmodifi
result
verifi
higher
cytotox
combin
therapi
compar
chemoor
phototherapi
alon
approach
control
number
aptam
surfac
nanoparticl
offer
versatil
function
method
techniqu
base
dna
strand
conjug
surfac
nanoparticl
complementari
fit
intend
aptam
baek
et
al
use
complementari
dna
strand
cdna
conjug
dspepegmaleimid
phospholipid
thiolat
linker
postinsert
preform
pegyl
liposom
antiprostatespecif
membran
antigen
aptam
antipsma
aptam
pair
cdna
strand
conjug
surfac
preform
liposom
formul
test
vitro
psma
cell
line
lncap
mous
model
xenograft
human
prostat
cancer
doxorubicin
encapsul
insid
liposom
use
ph
gradientdriven
method
dnabas
nanostructur
selfassembl
pyramid
cage
compos
four
oligonucleotid
introduc
charoenphol
bermudez
dna
nanostructur
allow
therapeut
molecul
encapsul
within
interior
space
intercal
along
doublehel
edg
incorpor
part
structur
aptam
conjug
dna
pyramid
modifi
poli
adenin
rna
aptam
bound
complementari
poli
thymin
residu
dnabas
nanostructur
aptamerdisplay
pyramid
found
significantli
resist
nucleas
degrad
enhanc
intracellular
uptak
select
inhibit
growth
cancer
cell
anoth
interest
dna
icosahedra
nanostructur
load
doxorubicin
target
breast
cancer
cell
function
aptam
cdna
strand
conjug
aptamerconjug
dna
icosahedra
nanostructur
show
effici
specif
intern
kill
epitheli
cancer
cell
polyplex
compos
cation
polym
polyethyleneimin
pei
plasmid
dna
pdna
contain
firefli
luciferas
gene
prepar
polyplex
electrostat
conjug
aptam
surfac
form
complex
aptamerguid
polyplex
show
higher
gene
express
mous
xenograft
model
human
lung
cancer
use
tumortarget
gene
deliveri
system
high
transfect
effici
zhao
et
al
test
peicitr
nanocomplex
anaplast
lymphoma
kinas
alk
sirna
function
aptam
via
noncoval
bond
target
human
anaplast
larg
cell
lymphoma
alcl
target
nanocomplex
specif
silenc
alk
gene
express
lead
growth
arrest
apoptosi
nanocomplex
formula
adapt
subramanian
et
al
electrostat
epcam
aptam
epapt
breast
cancer
cell
line
epapt
nanocomplex
abl
target
epcam
tumor
cell
deliv
sirna
silenc
target
gene
anoth
target
deliveri
system
base
dendrim
hybrid
singlestrand
psma
prostatespecif
membran
antigen
rna
aptam
follow
doxorubucin
chelat
exampl
base
pair
cdnamedi
dendrimeraptam
conjug
nanocarri
reveal
promis
possibl
chemoimmuno
therapeut
system
prostat
cancer
vivo
vitro
model
similarli
base
pair
cdnamedi
dendrimeraptam
conjug
strategi
also
adapt
conjug
threearm
yshape
dendrit
dna
nanostructur
formul
exert
strong
toxic
human
tcell
acut
lymphoblast
leukemia
cell
line
avidin
tetramer
biotinbind
protein
tetramer
protein
contain
four
ident
subunit
homotetram
bind
biotin
vitamin
vitamin
h
high
degre
affin
specif
dissoci
constant
avidinbiotin
complex
measur
make
one
strongest
known
noncoval
bond
bind
approach
adapt
ninomiya
et
al
conjug
biotinyl
aptam
avidintr
liposom
avidinbiotin
coupl
figur
antiplateletderiv
growth
factor
receptor
aptam
surfacelink
doxorubicinliposom
sensit
use
poli
nipmamconipam
thermosensit
polym
lower
viabil
observ
breast
cancer
cell
line
treat
doxorubicinload
aptamerfunction
liposom
ultrasound
irradi
compar
cell
viabil
without
ultrasound
irradi
avidin
tetramer
biotinbind
protein
tetramer
protein
contain
four
ident
subunit
homotetram
bind
biotin
vitamin
vitamin
h
high
degre
affin
specif
dissoci
constant
avidinbiotin
complex
measur
make
one
strongest
known
noncoval
bond
bind
approach
adapt
ninomiya
et
al
conjug
biotinyl
aptam
avidintr
liposom
avidinbiotin
coupl
figur
antiplateletderiv
growth
factor
receptor
aptam
surfacelink
doxorubicinliposom
sensit
use
poli
nipmamconipam
thermosensit
polym
lower
viabil
observ
breast
cancer
cell
line
treat
doxorubicinload
aptamerfunction
liposom
ultrasound
irradi
compar
cell
viabil
without
ultrasound
irradi
zhou
et
al
develop
multifunct
aptamerfunction
doxorubicinload
calcium
carbon
cc
nanostructur
platform
aptccn
crosslink
avidin
membran
surfac
ccn
prepar
bind
biotinmodifi
aptam
prepar
aptamermodifi
doxload
ccn
nanostructur
platform
show
accur
cell
target
control
drug
releas
zhou
et
al
develop
multifunct
aptamerfunction
doxorubicinload
calcium
carbon
cc
nanostructur
platform
aptccn
crosslink
avidin
membran
surfac
ccn
prepar
bind
biotinmodifi
aptam
prepar
aptamermodifi
doxload
ccn
nanostructur
platform
show
accur
cell
target
control
drug
releas
aptamerconjug
rubpydop
silica
nanoprob
test
human
breast
carcinoma
cell
label
nanoprob
made
avidinbiotin
coupl
biotinlabel
aptam
avidinfunction
silica
np
avidinfsinp
biotinmodifi
aptam
use
identifi
ccrfcem
cell
tall
cell
line
biotinappend
qd
label
aptam
via
streptavidin
biotin
amplif
interact
result
reveal
complex
could
effect
diagnos
leukemia
earli
stage
potenti
imag
tumor
cell
vitro
vivo
earli
diagnosi
diseas
strength
thiolgold
coordin
interact
provid
basi
fabric
robust
selfassembl
monolay
divers
applic
attach
thiolat
nucleic
acid
gold
nanoparticl
aunp
enabl
mani
mileston
achiev
nanobiotechnolog
figur
aptam
conjug
gold
nanostar
synthes
nanoconstruct
thiolat
attach
aun
surfac
via
bond
saltag
process
nanoconstruct
test
cancer
cell
line
repres
four
cancer
subcategori
show
enhanc
vitro
efficaci
result
increas
aptam
stabil
high
local
concentr
result
reveal
complex
could
effect
diagnos
leukemia
earli
stage
potenti
imag
tumor
cell
vitro
vivo
earli
diagnosi
diseas
strength
thiolgold
coordin
interact
provid
basi
fabric
robust
selfassembl
monolay
divers
applic
attach
thiolat
nucleic
acid
gold
nanoparticl
aunp
enabl
mani
mileston
achiev
nanobiotechnolog
figur
aptam
conjug
gold
nanostar
synthes
nanoconstruct
thiolat
attach
aun
surfac
via
bond
saltag
process
nanoconstruct
test
cancer
cell
line
repres
four
cancer
subcategori
show
enhanc
vitro
efficaci
result
increas
aptam
stabil
high
local
concentr
strong
linkag
util
decor
gold
nanoparticl
au
np
aptam
tether
pair
cgatcga
sequenc
approach
au
np
new
platform
use
nanocarri
codeliv
photosensit
porphyrin
doxorubicin
target
tumor
cell
hela
doxresist
cell
line
photodynam
stimul
platform
enhanc
doxorubicin
releas
cancer
cell
higher
cytotox
compar
free
doxorubicin
aptam
select
ccrfcem
cell
tcell
acut
lymphoblast
leukemia
cell
line
tether
hairpin
dnagold
nanoparticl
conjug
goldthiol
linkag
cgatcg
sequenc
within
hairpin
dna
gold
nanoparticl
surfac
use
doxorubicin
intercal
construct
nanoconjug
accommod
high
drug
load
show
specif
recognit
tumor
cell
addit
trigger
releas
encapsul
molecul
expos
laser
illumin
strong
linkag
util
decor
gold
nanoparticl
au
np
aptam
tether
pair
cgatcga
sequenc
approach
au
np
new
platform
use
nanocarri
codeliv
photosensit
porphyrin
doxorubicin
target
tumor
cell
hela
doxresist
cell
line
photodynam
stimul
platform
enhanc
doxorubicin
releas
cancer
cell
higher
cytotox
compar
free
doxorubicin
thiolmodifi
aptam
select
ccrfcem
cell
tcell
acut
lymphoblast
leukemia
cell
line
tether
hairpin
dnagold
nanoparticl
conjug
goldthiol
linkag
cgatcg
sequenc
within
hairpin
dna
gold
nanoparticl
surfac
use
doxorubicin
intercal
construct
nanoconjug
accommod
high
drug
load
show
specif
recognit
tumor
cell
addit
trigger
releas
encapsul
molecul
expos
laser
illumin
thiolat
aptam
function
gold
nanoparticl
via
sulfurgold
linkag
synthes
target
tcell
acut
lymphoblast
leukemia
daunorubicin
antitumor
drug
chelat
cgrich
sequenc
aptam
result
aptdaunorubicinau
nanoparticl
show
higher
intern
deliveri
drug
cell
better
releas
respons
slightli
acid
ph
photodynam
phototherm
cancer
therapi
multimod
compos
aptam
switch
probe
asp
attach
photosensit
molecul
chlorin
test
differ
leukemia
cell
line
photosensit
connect
end
asp
via
coupl
carboxyl
group
molecul
amino
group
end
aptam
polyt
chain
link
end
eightbas
segment
complementari
end
sulfhydryl
group
attach
aunr
composit
enhanc
target
bind
provid
high
specif
therapeut
effici
anoth
effici
phototherm
therapi
base
aptamerconjug
auag
nanorod
test
mix
cancer
cell
huang
et
al
select
aptam
thiol
modif
attach
nanorod
surfac
simpl
thiolau
linkag
aptamerfunction
nanorod
kill
ccrfcemm
cell
compar
cell
death
control
cell
nanocomposit
nanoparticlehybrid
graphen
oxid
design
phototherm
treatment
human
breast
cancer
cell
aptam
link
gold
nanoparticl
via
sulfurgold
linkag
facilit
target
treatment
tumor
cell
figur
phototherm
treatment
led
target
inhibit
breast
cancer
cell
growth
induc
apoptosi
provid
high
specif
therapeut
effici
anoth
effici
phototherm
therapi
base
aptamerconjug
auag
nanorod
test
mix
cancer
cell
huang
et
al
select
aptam
modif
attach
surfac
simpl
thiolau
linkag
aptamerfunction
nanorod
kill
ccrfcemm
cell
compar
cell
death
control
cell
nanocomposit
nanoparticlehybrid
graphen
oxid
design
phototherm
treatment
human
breast
cancer
cell
aptam
link
gold
nanoparticl
via
sulfurgold
linkag
facilit
target
treatment
tumor
cell
figur
phototherm
treatment
led
target
inhibit
breast
cancer
cell
growth
induc
apoptosi
zhao
et
al
util
approach
dual
target
au
shellcoatedliposom
sulfhydryl
aptam
aptam
preform
liposom
mix
gold
salt
form
uniformli
distribut
au
shell
surfac
follow
sulfhydrylaptam
coordin
gold
nanoparticl
liposom
load
docetaxel
ammonium
chlorid
dual
ligand
function
significantli
increas
cellular
uptak
breast
cancer
cell
line
cell
show
higher
tumor
suppress
compar
singl
target
one
aptam
conjug
strategi
involv
periodatemedi
reaction
phenylen
diaminesubstitut
aptam
anilin
group
instal
outer
surfac
nanoparticl
figur
zhao
et
al
util
approach
dual
target
au
shellcoatedliposom
sulfhydryl
aptam
aptam
preform
liposom
mix
gold
salt
form
uniformli
distribut
au
shell
liposom
surfac
follow
sulfhydrylaptam
coordin
gold
nanoparticl
liposom
load
docetaxel
ammonium
chlorid
dual
ligand
function
significantli
increas
cellular
uptak
breast
cancer
cell
line
cell
show
higher
tumor
suppress
compar
singl
target
one
aptam
conjug
strategi
involv
periodatemedi
reaction
phenylen
diaminesubstitut
aptam
anilin
group
instal
outer
surfac
nanoparticl
figur
approach
mainli
appli
biomimet
nanocarri
exampl
bacteriophag
viru
protein
coat
sequenceident
monom
express
selfassembl
escherichia
coli
arrang
hollow
spheric
nanostructur
robust
safe
biodegrad
genomefre
nanostructur
mani
pore
encapsul
activ
medic
ingredi
addit
possibl
interior
exterior
bioconjug
interior
load
porphyrin
capabl
produc
cytotox
singlet
oxygen
upon
illumin
surfac
function
aptam
target
protein
tyrosin
kinas
receptor
jurkat
leukemia
cell
method
includ
chemoselect
coupl
n
diamin
moieti
attach
aptam
anilin
residu
capsid
surfac
presenc
sodium
period
anilin
coupl
partner
introduc
exterior
surfac
capsid
either
direct
chemic
modif
introduct
unnatur
amino
acid
paminophenylalanin
paf
posit
coat
protein
use
amber
stop
codon
suppress
system
figur
target
biomimet
nanocarri
select
target
kill
tumor
cell
min
illumin
approach
mainli
appli
biomimet
nanocarri
exampl
bacteriophag
viru
protein
coat
sequenceident
monom
express
selfassembl
escherichia
coli
arrang
hollow
spheric
nanostructur
robust
safe
biodegrad
genomefre
nanostructur
mani
pore
encapsul
activ
medic
ingredi
addit
possibl
interior
exterior
bioconjug
interior
load
porphyrin
capabl
produc
cytotox
singlet
oxygen
upon
illumin
surfac
function
aptam
target
protein
tyrosin
kinas
receptor
jurkat
leukemia
cell
method
includ
chemoselect
coupl
n
ndiethyln
acylphenylen
diamin
moieti
attach
aptam
anilin
residu
capsid
surfac
presenc
sodium
period
naio
anilin
coupl
partner
introduc
exterior
surfac
capsid
either
direct
chemic
modif
introduct
unnatur
amino
acid
paminophenylalanin
paf
posit
coat
protein
use
amber
stop
codon
suppress
system
figur
target
biomimet
nanocarri
select
target
kill
tumor
cell
min
illumin
approach
mainli
appli
biomimet
nanocarri
exampl
bacteriophag
viru
protein
coat
sequenceident
monom
express
selfassembl
escherichia
coli
arrang
hollow
spheric
nanostructur
robust
safe
biodegrad
genomefre
nanostructur
mani
pore
encapsul
activ
medic
ingredi
addit
possibl
interior
exterior
bioconjug
interior
load
porphyrin
capabl
produc
cytotox
singlet
oxygen
upon
illumin
surfac
function
aptam
target
protein
tyrosin
kinas
receptor
jurkat
leukemia
cell
method
includ
chemoselect
coupl
n
diamin
moieti
attach
aptam
anilin
residu
capsid
surfac
presenc
sodium
period
anilin
coupl
partner
introduc
exterior
surfac
capsid
either
direct
chemic
modif
introduct
unnatur
amino
acid
paminophenylalanin
paf
posit
coat
protein
use
amber
stop
codon
suppress
system
figur
target
biomimet
nanocarri
select
target
kill
tumor
cell
min
illumin
coppercatalyz
azidealkyn
cycloaddit
reaction
wide
use
connect
molecular
entiti
size
figur
coppercatalyz
azidealkyn
cycloaddit
reaction
wide
use
connect
molecular
entiti
size
figur
aptamerpolym
hybrid
aph
synthes
base
coupl
aptam
polyeth
click
chemistri
use
tricarboxyl
ligand
stabil
cu
cycloaddit
aph
molecul
load
doxorubicin
activ
intern
via
endocytosi
cell
select
kill
nucleolinexpress
target
cell
figur
tabl
repres
summari
variou
conjug
strategi
aptam
differ
nanoparticl
drug
target
cancer
cell
aptamerpolym
hybrid
aph
synthes
base
coupl
n
aptam
polyeth
click
chemistri
use
tricarboxyl
ligand
stabil
cu
cycloaddit
aph
molecul
load
doxorubicin
activ
intern
via
endocytosi
cell
select
kill
nucleolinexpress
target
cell
figur
aptamerpolym
hybrid
aph
synthes
base
coupl
aptam
polyeth
click
chemistri
use
tricarboxyl
ligand
stabil
cu
cycloaddit
aph
molecul
load
doxorubicin
activ
intern
via
endocytosi
cell
select
kill
nucleolinexpress
target
cell
figur
tabl
repres
summari
variou
conjug
strategi
aptam
differ
nanoparticl
drug
target
cancer
cell
function
give
aptamerpolym
cuaac
reaction
tabl
repres
summari
variou
conjug
strategi
aptam
differ
nanoparticl
drug
target
cancer
cell
although
aptam
low
toxic
immunogen
demonstr
major
studi
publish
literatur
report
case
indic
administr
dose
aptam
associ
degre
toxic
immunogen
exampl
macugen
antivegf
aptam
show
minim
toxic
seriou
drugrel
side
effect
inject
singl
multipl
dose
human
anim
previous
mention
studi
demonstr
safeti
macugen
local
administr
eye
thu
system
administr
aptam
might
alway
show
level
safeti
macugen
furthermor
macugen
aptam
proven
clinic
safeti
extend
period
two
year
aptam
test
futur
clinic
trial
might
reveal
contradict
result
polyanion
natur
aptam
may
result
nonspecif
interact
human
serum
protein
could
lead
aptam
accumul
tissu
caus
specif
case
seriou
possibl
lifethreaten
side
effect
toxic
immunogen
aptam
may
also
result
chemic
modif
exampl
phosphorothiol
aptam
associ
activ
complement
system
pattern
recognit
receptor
prr
part
innat
immun
system
detect
foreign
nucleic
acid
aptam
contain
cpg
may
resembl
pathogenassoci
molecular
pattern
pamp
trigger
innat
immun
system
induc
express
deleteri
cytokin
addit
lna
aptam
impos
signific
risk
hepatotox
modifi
aptam
hydrophob
moieti
increas
promiscu
potenti
increas
toxic
also
lipophil
particl
low
hepat
clearanc
rna
aptam
modifi
fluoro
group
repres
anoth
chemic
modif
might
concern
sinc
aptam
may
activ
prr
although
may
advantag
cancer
therapi
may
also
produc
unwant
side
effect
exampl
fluoro
pyrimidinemodifi
aptam
enhanc
activ
retino
acidinduc
gene
increas
apoptosi
express
human
cancer
cell
hand
omethyl
pyrimidin
fail
induc
immun
respons
immun
system
may
produc
antibodi
pegyl
aptam
exampl
phase
trial
evalu
pegnivacogin
pegyl
rna
aptam
report
allerg
reaction
induc
aptam
conclus
even
though
aptam
may
perform
anticip
clinic
trial
still
consid
safer
altern
antibodi
nonetheless
extens
clinic
evalu
toxic
immunogen
highli
recommend
product
safer
aptam
gener
aptam
specif
nucleic
acidbas
bind
ligand
refin
properti
make
good
candid
variou
biomed
applic
diagnost
therapeut
target
drug
deliveri
level
sinc
discoveri
aptam
sever
chemic
modif
introduc
enhanc
resist
nucleas
improv
stabil
vivo
target
ligand
aptam
success
conjug
nanocarri
drug
molecul
nucleic
acid
success
implic
select
target
deliveri
therapeut
payload
target
cell
current
sever
aptam
variou
stage
clinic
trial
mani
alreadi
show
promis
preclin
data
field
aptam
rel
new
grow
bodi
evid
contribut
significantli
futur
advanc
new
gener
target
therapeut
aptam
stand
remark
new
famili
medicin
agent
place
convent
organ
molecul
biolog
drug
aptam
size
advantag
easili
chemic
synthes
larg
nontox
nonimmunogen
high
affin
specif
compar
antibodi
aptam
synthes
select
rang
target
effici
despit
advantag
aptam
suffer
decreas
vivo
stabil
high
renal
excret
chemic
modif
aptam
enhanc
pharmacokinet
properti
improv
bioavail
moreov
aptam
chemic
physic
conjug
differ
type
drug
even
target
nanoparticl
expand
rang
medic
applic
